Roflumilast - Alliance Healthcare
Alliance Healthcare
Description
Roflumilast is a phosphodiesterase type-4 inhibitor with anti-inflammatory properties.
• Adult: 250 mcg once daily for 28 days, then 500 mcg once daily for maintenance.
Indications
Use in conjunction with bronchodilators for the maintenance of patients with COPD associated with chronic bronchitis.
Contraindications
The manufacturer suggests avoiding if there is any hepatic impairment present, pregnancy or breast feeding.
Preparations Available
Tablets
Sizes Available
Tablets
500 mcg, 30 tablets
More on: Xanthines , Roflumilast